Drug
Diroximel fumarate clinical trials
Also written Vumerity, BIIB098 and ALK8700.
Keep track of what changes. Save the diroximel fumarate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
Biogen (5) · University of Nebraska (1) · King's College London (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses diroximel fumarate is read from its arms, and is right about nine times in ten.
Testing it · 7
- Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery DiseaseRecruitingEarly Phase 1University of NebraskaNCT06319339Written as Vumerity
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Not yet recruitingPhase 3BiogenNCT07483632Written as Diroximel Fumarate
- Investigating the Effect of Diroximel Fumarate on Glutathione in SchizophreniaRecruitingNot applicableKing's College LondonNCT06957808Written as Diroximel fumarate (DRF)
- A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)CompletedPhase 3BiogenNCT05083923Written as Diroximel fumarate
- A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1CompletedPhase 3BiogenNCT02634307Written as ALKS 8700
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy ParticipantsCompletedPhase 1BiogenNCT05127564Written as Diroximel fumarate
- A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2CompletedPhase 3BiogenNCT03093324Written as ALKS 8700
As the comparator · 1 — what is tested is compared with diroximel fumarate
Codes
What other systems call diroximel fumarate · ClinicalTrials.gg INT001853
- MeSH (NLM) C000722501diroximel fumarateOne source ClinicalTrials.gov
- UNII (FDA) K0N0Z40J3WDIROXIMEL FUMARATEConfirmed FDA, Wikidata
- RxNorm 2261783One source FDA
- Wikidata Q27281786diroximel fumarateConfirmed FDA, Wikidata
- NCI Thesaurus C169916Diroximel FumarateOne source FDA
- DrugBank DB14783One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722501 | diroximel fumarate | One source ClinicalTrials.gov |
| UNII (FDA) | K0N0Z40J3W | DIROXIMEL FUMARATE | Confirmed FDA, Wikidata |
| RxNorm | 2261783 | — | One source FDA |
| Wikidata | Q27281786 | diroximel fumarate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C169916 | Diroximel Fumarate | One source FDA |
| DrugBank | DB14783 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.